|
|
|
|
GILD: Does it pass the trial as a long-term investment? |
|
Stephanie Chung parses the Sovaldi-maker's growth prospects |
|
| I like the biotech industry for two reasons: one is the moral benefit of knowing you are investing in a good cause, and the other is the prospect of momentous returns, as is the case with Gilead Sciences (GILD). Nevertheless, I am usually deterred by the volatile nature of this industry, in which companies' profits depend on trial results, approvals, and patent durations....Read more. |
| |
|
|
Make the Most of Your Membership |
|
This month we are featuring some of our favorite recorded webinars |
|
|
|
Get the Guide to Stock Rover Premium, a PDF companion to your membership, with an overview of all Premium benefits and tips for making them most of them. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Thank you, as always, for your interest in Stock Rover.
Wishing you a productive week,
The Stock Rover Team |
|
| |
|
|
|
|
Options >> Account Settings >> Email Notifications |
|
